Expert Presentations - Data Interpretation

Case Study: Real-Life Application of CGM Data Interpretation

LBL-1003028 REV002 Stepwise approach PDF.pdf

Related Resources

Premium Content

Off

The Role of CGM and Automated Insulin Delivery (AID) Systems in Pregnancy

OlgaDalisay — Tue, 21 May 2024 17:32:55 +0000

The Role of CGM and Automated Insulin Delivery (AID) Systems in Pregnancy

05/24/2024

OlgaDalisay Tue, 05/21/2024 - 17:32

A perspective from the United Kingdom

^{The information you see or hear at this event provides details about medical products which are not available in all countries, may have different indications, and/or have not received approval or market clearance by all governmental regulatory bodies throughout the world. Nothing shown or stated herein should be construed as a solicitation, advertisement, or promotion of any product, or of an indication of any specific use for any product, which is not authorized by the laws and regulations of the country where you reside.}

^{The content may include the presenter’s own experience sharing and data – please do not record or distribute the presentation slides.}

This short presentation was delivered during the recent ATTD Diabetes Congress in Italy.

Managing diabetes during pregnancy is critical for maternal and fetal health. Pregnancy induces physiological changes that affect insulin sensitivity, complicating glycemic control.¹ Poorly managed diabetes can lead to adverse outcomes such as preeclampsia, preterm birth, and congenital malformations.² Utilizing continuous glucose monitoring (CGM) technology allows for real-time glucose tracking, facilitating tighter glycemic control.³ This proactive management is essential in minimizing hyperglycemia and hypoglycemia, thus improving both maternal and neonatal outcomes.⁴ Close monitoring and interdisciplinary care are vital for optimizing pregnancy outcomes in women with diabetes.⁵

Dr Helen Murphy is a Professor of Medicine (Diabetes and Antenatal Care) at the University of East Anglia, and a practicing clinician (Norfolk & Norwich University Hospital NHS Trust), Norwich, UK.

She runs a diabetes pregnancy research program which aims to support women with diabetes to achieve the pregnancy glucose targets required for optimal mother and baby health outcomes. She co-led the CONCEPTT Continuous Glucose Monitoring (CGM) trial. CONCEPTT demonstrated health benefits for mothers with type 1 diabetes (T1D), their newborn infants and the potential for substantial healthcare cost savings. In addition to scientific contributions, building research infrastructure and supporting the next generation of clinical academics, data from CONCEPTT led to international changes in clinical practice, CGM is now the recognized standard of care for pregnant women with T1D.

In this short ~20 min presentation, Dr Murphy will talk about the specifics of diabetes management in pregnant individuals across the United Kingdom, including:

National Diabetes in Pregnancy Audit
CGM use before and during Type 1 diabetes pregnancy
AiDAPT randomized trial results

^{Catalano, P. M., & Tyzbir, E. D. (1991). Effects of pregnancy on insulin sensitivity and beta-cell function in women with and without gestational diabetes.}^{American Journal of Obstetrics and Gynecology}^{, 165(3), 579-585.}
^{Reece, E. A., Leguizamon, G., & Wiznitzer, A. (2009). Gestational diabetes: the need for a common ground.}^{The Lancet}^{, 373(9677), 1789-1797.}
^{Voormolen, D. N., de Wit, L., van Rijn, B. B., Koster, M. P., de Valk, H. W., & Franx, A. (2018). Continuous glucose monitoring during pregnancy: An overview of recent studies.}^{Journal of Diabetes Science and Technology}^{, 12(5), 955-960.}
^{Murphy, H. R., et al. (2008). Effectiveness of continuous glucose monitoring in pregnant women with diabetes: randomised clinical trial.}^BMJ^{, 337, a1680.}
^{Yogev, Y., & Langer, O. (2008). Pregnancy outcome in diabetic patients.}^{Best Practice & Research Clinical Obstetrics & Gynaecology}^{, 22(6), 1041-1057}

Expert Presentations - Automated Insulin Delivery

Clinical Evidence - Automated Insulin Delivery

Pregnancy

Premium Content

The Future of EHR and CGM Integration

OlgaDalisay — Mon, 22 Apr 2024 20:26:21 +0000

The Future of EHR and CGM Integration

04/22/2024

OlgaDalisay Mon, 04/22/2024 - 20:26

Presented at ATTD 2024

In this short ~13 min presentation, you will hear from Grazia Aleppo, MD, FACE, FACP on how Northwestern Medicine/ Northwestern University have developed a new process to integrate CGM data into their EHR records.

Dr Aleppo will cover the following in this patient-centric approach:

Patient Identification process
Establishing the workflow
Improvements in billing & documentation and more

^{The content may include the presenter’s own experience sharing and data – please do not record or distribute the presentation slides.}

Events

Ambulatory Glucose Profile (AGP) Report: The EKG of Diabetes Management

ATTD

Country

Australia

United States

Grazia Aleppo, MD, FACE, FACP

Dr Aleppo’s clinical interest and research interest is in Diabetes, particularly Diabetes Technology including Insulin pump therapy and CGM in clinical practice. She has participated in major clinical trials incorporating CGM in various populations and automated insulin delivery systems. She is very active in scholarly activities with over 60 publications and book chapters in peer reviewed journals.

Related Resources

Premium Content

ATTD 2024 Symposia: Making the Invisible Visible in Type 2 Diabetes

OlgaDalisay — Thu, 21 Mar 2024 21:47:24 +0000

ATTD 2024 Symposia: Making the Invisible Visible in Type 2 Diabetes

03/21/2024

OlgaDalisay Thu, 03/21/2024 - 21:47

Dexcom Transformation: Improving Lives of People with Type 2 Diabetes

^{The content may include the presenter’s own experience sharing and data – please do not record or distribute the presentation slides.}

Watch this short ~24 min video on the new research from multiple studies presented at the Advanced Technologies & Treatments for Diabetes (ATTD) on March 6-9, 2024. Uncover a dual perspective, examining both the attainment of clinical goals as well as qualitative, patient-reported outcomes that spotlight how individuals leverage Dexcom CGM to successfully understand the impact of lifestyle choices that help inform personalized diabetes management goals.

Thomas Grace, MD will discuss the Dexcom Community Glucose Monitoring Project that studied individuals living with type 2 diabetes in Findlay, OH.

Participants (n=237) who were new to CGM, were given CGM along with routine diabetes management care experienced an A1C reduction of 2.4% at 6 months. Study participants also experienced clinically meaningful improvements in time in range (TIR) and time in tight range (TITR) as well as reductions in time above range (TAR).
The percentage of participants with an A1C under 7% increased from 0.4% at baseline to 54.0% at follow-up. The percentage of participants with an A1C above 8% increased from 18.6% at baseline to 82.7% at follow-up.

Starting CGM early in the diabetes diagnosis provides both individuals and PCPs with a tool to guide decision making, measure progress, and increase patient self-efficacy.

Study results also showed other benefits of starting CGM with minimal clinical oversight, and significant value was found from initiating CGM early in diabetes care:

How various factors affect their glucose levels and see the impact of behavior changes.
What was happening to their glucose levels allowed them to make informed decisions about what they eat.
Greater feeling of control over their diabetes and improved confidence.

Clinical Evidence - Type 2 Diabetes

ATTD

Country

United States

Australia

Thomas Grace, MD, CDCES

Thomas Grace is a Family Medicine doctor in Findlay, Ohio. Dr. Grace and is rated as a Distinguished doctor by MediFind in the treatment of Type 2 Diabetes (T2D). He is also highly rated in 2 other conditions, according to our data. His top areas of expertise are Type 2 Diabetes (T2D), Maturity Onset Diabetes of the Young, Sepsis, Type 1 Diabetes (T1D), and Pacemaker Implantation.

His clinical research consists of co-authoring 3 peer reviewed articles and participating in 1 clinical trial in the past 15 years. In particular, he has co-authored 1 article and participated in 1 clinical trial in the study of Type 2 Diabetes (T2D).

William H. Polonsky, PhD, CDCES

Dr. Polonsky is President and Founder of the Behavioral Diabetes Institute, the world's first organization wholly dedicated to studying and addressing the unmet psychological needs of people with diabetes. He is also Associate Clinical Professor in Psychiatry at the University of California, San Diego. Dr. Polonsky received his PhD in clinical psychology from Yale University and has served as Senior Psychologist at the Joslin Diabetes Center in Boston, faculty member at Harvard Medical School and Chairman of the National Certification Board for Diabetes Educators.

Related Resources

Real-Time CGM as a Motivational Support Tool in Type 2 Diabetes

ATTD 2024 Symposia: CGM Improves Outcomes in Non-Insulin Treated Type 2 Diabetes

Premium Content

Case Study: Real-Life Application of CGM Data Interpretation

OlgaDalisay — Mon, 18 Mar 2024 23:17:55 +0000

Case Study: Real-Life Application of CGM Data Interpretation

03/18/2024

OlgaDalisay Mon, 03/18/2024 - 23:17

Learn how an AGP report can provide more informed decision-making, insights into therapy adjustments, and transform patients' overall well-being.

In this short ~6 min video, David Doriguzzi, PA-C, goes over a recent case study in his practice showcasing the journey of a patient with T2D who achieved significant improvements in their glycemic metrics by adding real-time CGM to the treatment plan. With addition of CGM to the picture, this patient had increased their time in target glucose range by almost 50% in just 1 month.

"...we are really only able to dial in [medication] by having an understanding of where the patient started, what her needs were, and how her glucose responded at different times of the day based on that CGM data ..."

Finally, Dr Doriguzzi goes over the specifics of CGM interpretation reimbursement criteria.

More about AGP report and Data Interpretation.

Expert Presentations - Reimbursement

Data Interpretation

Country

United States

David Doriguzzi, PA-C

David Doriguzzi, PA-C has been practicing since 2002 in internal medicine and endocrinology. He graduated from Loma Linda University PA program in 2002 and specializes primarily in diabetes and thyroid management. He works in Lancaster, CA as a physician assistant and is actively involved in educating other healthcare providers in the area of diabetes management.

Premium Content

Innovations Designed to Empower Clinicians, Educators and Caregivers

OlgaDalisay — Mon, 18 Dec 2023 16:38:27 +0000

Innovations Designed to Empower Clinicians, Educators and Caregivers

12/18/2023

OlgaDalisay Mon, 12/18/2023 - 16:38

Tune in to this ~17 min presentation from Diabetes Technology Meeting that took place virtually in November 2023. Peter Simpson, Sr Vice President of Advanced Research & Technology at Dexcom provides an overview of Dexcom's growing ecosystem of highly innovative solutions for diabetes management.

You will learn about current products and take a sneak peek at what's to come in the future for this rapidly evolving medical device technology. In addition, this presentation will cover:

Automated Insulin Delivery (AID) integrations and solutions that can provide your patients with more choice and personalization of their diabetes management
New Dexcom G7 enhancements
New integration with Tandem t:slim X2 pump
New Beta Bionics and Dexcom G7 Fully Closed Loop system

Expert Presentations - Automated Insulin Delivery

Diabetes Technology

Country

United States

Premium Content

EASD 2023: Diabetes Device Features Designed to Support Diabetes-Related Safety and Efficacy

OlgaDalisay — Thu, 02 Nov 2023 18:42:06 +0000

EASD 2023: Diabetes Device Features Designed to Support Diabetes-Related Safety and Efficacy

11/02/2023

OlgaDalisay Thu, 11/02/2023 - 18:42

In this 37 min presentation (includes Q&A) from EASD Annual Conference 2023, diabetes research expert Dr Battelino and Dr Hussain will discuss:

Cognitive decline and working memory complications associated with lower TIR
How CGM and AID systems can be used more effectively in various patient populations to improve outcomes

Dr Hussain will also talk about the new Dexcom G7 CGM system features, including:

The most device features designed to support diabetes related safety and efficacy (ULS, Delay 1st alert, Silence All)
Simple to start, easy to use and helps lower the burden of diabetes management
Exceptional accuracy for better informed treatment decisions

Clinical Evidence - Type 1 Diabetes

EASD 2023

Tadej Battelino, MD, PhD

Tadej Battelino obtained his MD at the Ljubljana Faculty of Medicine, where he also passed his board exam in pediatrics. He is currently a tenured professor of pediatrics at the Ljubljana Faculty of Medicine, and the head of Department of Pediatric endocrinology, diabetes and metabolism at the UMC - University Children’s Hospital Ljubljana, Slovenia. He serves as the Vice Dean for research at the Faculty of Medicine, University of Ljubljana, where he also serves as the Head of Chair of Pediatrics. He received numerous publicly funded grants in basic and clinical science.

Sufyan Hussain, MA, MB BChir, MRCP, PhD

Dr Sufyan Hussain is a consultant Diabetes and Endocrine Physician in one of the UK’s leading diabetes services at Guy’s and St Thomas Hospital and Honorary Senior Clinical Lecturer at King’s College London. He has a wide scope of practice both in the hospital and in community settings. His current research interests include hybrid-closed loops, understanding the support needs for using technologies effectively, diabetes distress and cell therapy in diabetes.

Dr Sufyan Hussain has over 31 years personal experience of living with type 1 diabetes and is passionate about improving care and advocacy for diabetes.

Premium Content

Why RT-CGM Early?

OlgaDalisay — Wed, 16 Aug 2023 17:19:11 +0000

Why RT-CGM Early?

08/16/2023

OlgaDalisay Wed, 08/16/2023 - 17:19

This short video is from this year's American Association of Physician Associates (AAPA) Conference, that was held in Nashville, TN in May. It highlights the benefits of RT-CGM for your patient's diabetes management, and latest clinical evidence supporting this topic.

Scott Urquhart, PA-C, DFAAPA

Diabetes and Thyroid Associates, Fredericksburg, VA. Founder / Chair, Metabolic and Endocrine Disease Summit (MEDS) Adjunct Clinical Professor, James Madison University PA program Clinical Instructor, George Washington University PA program

Clinical Evidence - Data Interpretation

Clinical Evidence - Type 1 Diabetes

Case Study: Real-Life Application of CGM Data Interpretation

Related Resources

CGM for Type 2 Diabetes Through the Lens of Healthcare Professionals

Premium Content

Highlights from APhA 2023

OlgaDalisay — Mon, 10 Apr 2023 23:43:22 +0000

Highlights from APhA 2023

04/10/2023

OlgaDalisay Mon, 04/10/2023 - 23:43

American Pharmacists Association (APhA) Annual Meeting brings together pharmacists from all practice settings and experience levels to connect and learn about new opportunities to transform the future of pharmacy care.

As continuous glucose monitoring becomes more accessible in pharmacy, we invite you to revisit this product theater to learn about:

- The latest in CGM technology

- How to identify new patients who can benefit from this technology

- New features of the Dexcom CGM that can benefit patients with Type 1 and Type 2 diabetes.

In addition, we will review stepwise approach to data interpretation using Dexcom Clarity.

Presenter:

For your convenience, this presentation is broken down into 3 parts, each is its own separate topic, following the same patient case study.

Part 1. Introducing the Next Generation of CGM

Part 2. The Role of Dexcom Clarity in Data Interpretation

Part 3. CGM Reimbursement

You can learn more about the Stepwise Approach here.

Clinical Evidence - Data Interpretation

Data Interpretation

Data Interpretation

Country

United States

Premium Content

Ambulatory Glucose Profile (AGP) Report: The EKG of Diabetes Management

OlgaDalisay — Thu, 08 Dec 2022 22:32:08 +0000

Ambulatory Glucose Profile (AGP) Report: The EKG of Diabetes Management

12/08/2022

OlgaDalisay Thu, 12/08/2022 - 22:32

Cardiometabolic Health Congress (CMHC) leads the medical community’s effort to understand, treat, and prevent cardiometabolic-related risk factors and diseases, which now affect an estimated 47 million people in the U.S.

This presentation was recorded during the recent conference.During this session we will discuss:

The value of adding AGP metrics, such as time in range (TIR), to your diabetes management process.
Recent research that demonstrates the benefits of real-time CGM for people living with both type 2 and type 1 diabetes.
Case studies and will review AGP report data and discuss how to apply clinical guidelines to support diabetes medication selection.

Events

Data Interpretation